Specifically, these assays are Ventana SP142 for atezolizumab (anti-PD-L1) in patients with urothelial carcinoma, triple-negative breast cancer or NSCLC; Dako 28-8 for nivolumab (anti-PD1) in combination with ipilimumab (anti-CTLA-4) in patients with NSCLC and Dako 22C3 for pembrolizumab (anti-PD1) in different solid tumors [56]. The gene discussed is PDCD1; the disease is urothelial carcinoma.